Time
|
Duration
|
Type
|
Presenting person
|
Title
|
May 26th, Monday |
|
| 08:45 |
00:30:00 |
Invited oral |
Teresa Paszkowska-Reymer |
The Concept of the Central Strategic Program -
Innovative Medicines |
| 09:15 |
00:30:00 |
Invited oral |
Jan Lubiński |
Genetic contribution to all cancers: implications for pharmaceutical treatment |
| 09:45 |
00:30:00 |
Invited oral |
Zbigniew E. Fijałek |
Unusual application of X-Ray diffraction in drug control – searching for counterfeit and substandard pharmaceuticals |
| 10:15 |
00:20:00 |
Oral |
Krzysztof Brzózka |
Focus on drug discovery – new opportunities in life science sector in Poland. |
| 10:35 |
00:20:00 |
Oral |
Krystyna Gryz |
Registration dossier of chemical active substance |
| 11:25 |
00:20:00 |
Oral |
Małgorzata Jarończyk |
The ligand binding to the serotonin transporter |
| 11:45 |
00:20:00 |
Oral |
Katarzyna A. Kaźmierska |
Hydrogel coatings and a local drug delivery |
| 12:05 |
00:20:00 |
Oral |
Lech Kozerski |
Novel medium for monomer proteins structure elucidation. Human insulin structure in water/ acetonitrile solvent. Search for nonamyloidogenic conditions |
| 12:25 |
00:20:00 |
Oral |
Sebastian Kmiecik |
Protein modeling in silico: providing new targets for a drug design |
| 12:45 |
00:20:00 |
Oral |
Maria Kraj |
Bortezomib in multiple myeloma: treatment and retreatment.
A single center experience |
| 15:00 |
00:30:00 |
Invited oral |
Jan Barciszewski |
Human brain tumor therapy through interference RNA intervention |
| 15:30 |
00:30:00 |
Invited oral |
Krzysztof L. Krzystyniak |
Therapeutic monoclonal antibodies in clinical and scientific data* |
| 16:00 |
00:20:00 |
Oral |
Zbigniew J. Kamiński |
Synthesis and Screening of the Library of the Supramolecular Structures Formed by N-Lipidated Oligopeptides for Selection of Host Active as Artificial Esterase |
| 16:20 |
00:20:00 |
Oral |
Wojciech Łuniewski |
Synthesis of selected 14C radiolabelled compounds in recent investigations of new analytical method applied in accelerated drug development (EUMAPP). |
May 27th, Tuesday |
|
| 08:30 |
00:30:00 |
Invited oral |
Marek Chmielewski |
Strategies of the synthesis of oxa- and carba-penams and cephams |
| 09:00 |
00:30:00 |
Invited oral |
Jerzy Ostrowski |
Integrative genomics - an essential tool for development of molecular medicine |
| 09:30 |
00:20:00 |
Oral |
Maciej Mikina |
New phosphonate - based strategy for the synthesis of carbocyclic nucleosides: natural Neplanocin A and its unnatural enantiomer. |
| 09:50 |
00:20:00 |
Oral |
Zofia Mazerska |
Specific metabolism of antitumor agents with cytochrome P-450 isoenzymes |
| 10:10 |
00:20:00 |
Oral |
Krzysztof Kamiński |
N-Phenylamino derivatives of 3-substituted pyrrolidine-2,5-diones as potential anticonvulsant agents |
| 10:30 |
00:20:00 |
Oral |
Maria M. Kasprzak |
Cytotoxic and proapoptotic in vitro activity of two novel flavone complexes of ruthenium(II) |
| 11:20 |
00:20:00 |
Oral |
Agata B. Maciejczyk |
The role of the Office for Medicinal Products, Medical Devices and Biocidal Products in pharmacovigilance activities in Poland |
| 11:40 |
00:20:00 |
Oral |
Aleksandra E. Mościcka-Studzińska |
Electrically enhanced and controlled drug delivery through buccal mucosa |
| 12:00 |
00:20:00 |
Oral |
Marek T. Konieczny |
Comparison of traditional and new methods of drug discovery |
| 12:20 |
00:20:00 |
Oral |
Sławomir Jarosz |
Synthesis of higher carbon sugars. Unexpected rearrangement of higher sugar allylic alcohols |
| 12:40 |
00:20:00 |
Oral |
Alicja Nowaczyk |
Newest triazole derivative with antifungal activity:
a docking study |
| 15:00 |
00:30:00 |
Invited oral |
Sergiusz Markowicz |
Harnessing stem cells and dendritic cells for novel therapies |
| 15:30 |
00:30:00 |
Invited oral |
Teresa M. Brodniewicz |
Scope and requirements regarding preclinical and human clinical trials of a new medicinal product, including biotechnology and biosimilar products. |
May 28th, Wednesday |
|
| 08:30 |
00:30:00 |
Invited oral |
Barbara Nawrot |
Therapeutic applications of RNAi |
| 09:00 |
00:30:00 |
Invited oral |
Witold Danikiewicz |
Applications of Mass Spectrometry in the Analysis of Pharmaceuticals |
| 09:30 |
00:30:00 |
Invited oral |
Michał Fedoryński |
Phase Transfer Catalysis in pharmaceutical industry – where are we? |
| 10:00 |
00:20:00 |
Oral |
Marcin Nowogródzki |
Polyhydroxylated decalin derivatives – stereoselective approach from simple sugars via allyltin compounds |
| 10:20 |
00:20:00 |
Oral |
Agnieszka Zagórska |
Tricyclic theophylline derivatives with arylalkylpiperazinyl moiety as CNS agents |
| 10:40 |
00:20:00 |
Oral |
Stanisław Ryng |
Two examples of very closely related isoxazoles exhibiting opposite immunological activities |
| 11:30 |
00:30:00 |
Invited oral |
Gabriel Wcisło |
Molecular underpinnings of the targeted therapy for cancer |
| 12:00 |
00:30:00 |
Invited oral |
Tadeusz Pietrucha |
Overview of pharmaceutical biotechnology sector in Poland |
| 12:30 |
00:20:00 |
Oral |
Piotr T. Tarnowski |
LC/MS/MS as a tool for profiling metabolites of active substances |
| 12:50 |
00:20:00 |
Oral |
Maria Bretner |
Anti-glioma activity of selected CK2 protein kinase inhibitors |
| 13:10 |
00:20:00 |
Oral |
Stanisław Boryczka |
Synthesis and antiproliferative activity in vitro of (4-substituted-2-butynylthio)quinolines |
